Hsiao-Wei Liao

Prof. Dr. Hsiao-Wei Liao

National Yang-Ming University
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

17 April 2015 in BMC Cancer
Verified
Journal Article
Open access
PDF file
PWPei-Fang Wu
Pei-Fang Wu
CLCHING-HUNG LIN
CHING-HUNG LIN
CKChing-Hua Kuo
Ching-Hua Kuo
TCTom Wei-Wu Chen
Tom Wei-Wu Chen
DYDah-Cherng Yeh
Dah-Cherng Yeh
YLYen-Shen Lu
Yen-Shen Lu
Elevated vascular endothelial growth factor (VEGF) was associated with poor prognosis in leptomeningeal carcinomatosis and anti-angiogenic therapy was found to prolong the survival of mice in preclinical studies. This prospective pilot study investigated the efficacy of anti-VEGF therapy plus chemotherapy in patients with leptomeningeal carcinomatosis originating from breast cancer. Eligible patients were scheduled to receive bevacizumab combined with etoposide and cisplatin (BEEP) every 3 weeks for a maximum of 6 cycles or until unacceptable toxicity. The primary objective was the central nervous system (CNS)-specific response rate, which was defined as disappearance of cancer cells in the cerebrospinal fluid (CSF) and an improved or stabilized neurologic status. The impact of VEGF inhibition on etoposide penetration into the CSF was analyzed. Eight patients were enrolled. The CNS-specific response rate was 60% in 5 evaluable patients. According to intent-to-treat analysis, the median overall survival of the eight patients was 4.7 months (95% confidence interval, CI, 0.3–9.0) and the neurologic progression-free survival was 4.7 months (95% CI 0–10.5). The most common grade 3/4 adverse events were neutropenia (23.1%), leukopenia (23.1%), and hyponatremia (23.1%). The etoposide concentrations in the CSF were much lower than those in plasma, and bevacizumab did not increase etoposide delivery to the CSF. BEEP exhibited promising efficacy in breast cancer patients with leptomeningeal carcinomatosis. Additional studies are warranted to verify its efficacy and clarify the role of anti-angiogenic therapy in this disease. ClinicalTrials.gov identifying number NCT01281696 .

1 November 2009 in Journal of Chromatography A
Verified
Journal Article
Closed access
ITI-Lin Tsai
I-Lin Tsai
SSShao-Wen Sun
Shao-Wen Sun
Hsiao-Wei LiaoHsiao-Wei Liao
Hsiao-Wei Liao
SLShu-Chiao Lin
Shu-Chiao Lin
CKChing-Hua Kuo
Ching-Hua Kuo


1 June 2020 in Analytica Chimica Acta
Verified
Journal Article
Closed access
Hsiao-Wei LiaoHsiao-Wei Liao
Hsiao-Wei Liao
SRStanislav S. Rubakhin
Stanislav S. Rubakhin
MPMarina C. Philip
Marina C. Philip
JSJonathan Sweedler
Jonathan Sweedler

1 March 2017 in Journal of Chromatography A
Verified
Journal Article
Closed access
DCDivyabharathi Chepyala
Divyabharathi Chepyala
ITI-Lin Tsai
I-Lin Tsai
Hsiao-Wei LiaoHsiao-Wei Liao
Hsiao-Wei Liao
GCGuan-Yuan Chen
Guan-Yuan Chen
HCHsi-Chun Chao
Hsi-Chun Chao
CKChing-Hua Kuo
Ching-Hua Kuo